With 1.67 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.1 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $29.99 whereas the lowest price it dropped to was $28.32. The 52-week range on RNA shows that it touched its highest point at $56.00 and its lowest point at $8.86 during that stretch. It currently has a 1-year price target of $68.27. Beta for the stock currently stands at 0.95.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RNA was down-trending over the past week, with a drop of -8.30%, but this was down by -32.66% over a month. Three-month performance dropped to -36.47% while six-month performance fell -29.31%. The stock gained 212.75% in the past year, while it has gained 222.43% so far this year. A look at the trailing 12-month EPS for RNA yields -2.90 with Next year EPS estimates of -3.21. For the next quarter, that number is -0.79. This implies an EPS growth rate of 1.49% for this year and -12.10% for next year.
Float and Shares Shorts:
At present, 118.90 million RNA shares are outstanding with a float of 108.55 million shares on hand for trading. On 2024-12-13, short shares totaled 15.48 million, which was 1297.0 higher than short shares on 1731628800. In addition to Dr. Troy Edward Wilson J.D., Ph.D. as the firm’s Co-Founder & Independent Chairman, Ms. Sarah Boyce serves as its President, CEO & Director.
Institutional Ownership:
Through their ownership of 1.0625701 of RNA’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, RNA reported revenue of $2336000.0 and operating income of -$98134000.0. The EBITDA in the recently reported quarter was -$97424000.0 and diluted EPS was -$0.65.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RNA since 6 analysts follow the stock currently. There are 5 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With RNA analysts setting a high price target of 96.0 and a low target of 51.0, the average target price over the next 12 months is 68.27273. Based on these targets, RNA could surge 228.99% to reach the target high and rise by 74.78% to reach the target low. Reaching the average price target will result in a growth of 133.97% from current levels.
Analysts have provided yearly estimates in a range of -$2.69801 being high and -$2.98567 being low. For RNA, this leads to a yearly average estimate of -$2.86664. Based on analyst estimates, the high estimate for the next quarter is -$0.62 and the low estimate is -$0.95. The average estimate for the next quarter is thus -$0.76.
